DRAX EXAMETAZIME
Peakkit for the preparation of technetium tc 99m exametazime for leukocyte labeling
NDAINTRAVENOUSPOWDER
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DRAX EXAMETAZIME (kit for the preparation of technetium tc 99m exametazime for leukocyte labeling) by Jubilant Therapeutics is radiopharmaceutical activity [moa]. First approved in 2017.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DRAX EXAMETAZIME is a radiopharmaceutical kit for preparing Technetium Tc-99m exametazime, a diagnostic agent used to label leukocytes for imaging inflammatory and infectious lesions. It works via radiopharmaceutical activity, enabling clinicians to visualize white blood cell distribution and migration in real time. This is a specialty nuclear medicine product with narrow but critical applications in infectious disease and inflammation diagnostics.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), indicating stable demand but limited team expansion opportunity.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DRAX EXAMETAZIME is a specialized diagnostic product with limited linked job postings, reflecting its niche market focus within nuclear medicine. Career growth depends on hospital relationships, manufacturing expertise, and regulatory knowledge rather than broad commercial expansion.
Radiopharmaceutical SpecialistHospital Account Manager
Worked on DRAX EXAMETAZIME at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.